Page 87 - MemoriaBBN-Eng

www.ciber-bbn.es

• v C e, A e, r m, s-t C, G F, P-á l
Most relevant ACAsórdoBArnAizellosoánChezorresArCíAérezlvArezet
Al.. Development of sulphated and naphthylsulphonated carbosilane dendrimers
scientific as topical microbicides to prevent HIV-1 sexual transmission.AIDS. 2013 May

articles
15;27(8):1219-29.

• sePúlvedA-CresPo d, lorente r, leAl m, Gómez r, de lA mAtA FJ, Jiménez Jl et Al.. Syner-

gistic activity profile of carbosilane dendrimer G2-STE16 in combination with other
dendrimers and antiretrovirals as topical anti-HIV-1 microbicide.Nanomedicine.;.

• C ev, A e, d l m FJ, G r, l m, P m .. Synergistic activity
órdoBArnáizeAAtAómezeAlionet Al
of carbosilane dendrimers in combination with maraviroc against HIV in vitro.AIDS.
2013 Aug 24;27(13):2053-8.

• F-P e, P-G Ce, G m, G r, m FJ, s-n
uentesAniAGuAeñAonzálezAlánómezde lA AtAánChezieves
J. Thiol-Ene Synthesis of Cationic Carbosilane Dendrons: a New Family of Synthon-
sORGANOMETALLICS. 2013;32(6):1789-1796.

• i m, C K, m Br, A d, s-n J, G r, m
onoviePluChorenoPPelhAnsánChezievesómezde lA AtA
FJ, muñoz-Fernández mA, BryszeWsKA m. Biophysical Characterization of Glycodendri-

mers as Nano-carriers for HIV PeptidesCurrent Medicinal Chemistry. 2013;20(31):
3935-3943.

The activity of the group during 2013 has been centered in the development of
Highlights
new dendritic nanosystems in two directions: (i) design of improved non-viral

vectors for gene therapy in HIV and cancer and (ii) design of HIV antiviral, anti-
bacterial and anticancer agents funded by European (EURONANOMED), national

(CTQ2011-23245 (MINECO)) and regional (Consorcio NANODENMED-CM) pro-

jects . Research carried out, focused in the search of a new therapeutic approach
towards the HIV treatment based on peptides-associated dendrimers in dendritic

cells for the development of new nano-HIV vaccines within the framework of the
European project EURONANOMED or the use of anionic dendrimers as HIV anti-

viral systems and their use in therapy of combination. In addition, new dendritic

systems have been developed as carrier of double strand RNA in the treatment
of melanoma cancer within the Consortium NANODENMED-CM from Community

of Madrid, coordinated by our group.Results of the research have been presented

in several conferences, notably in the VIII International dendrimers Symposium
(IDS8) held in Madrid and organized by our group among others, and published

works consisted of 13 publications and 3 books chapters. The group has continued
intensifying its activities related to technology transfer applying for a PCT exten-

sion of one national patent based on the use of homo and hereto-functionalized

carbosilane dendrimers in VIH and cancer diseases.

13
20
T
OR
P
RE
L
A
NU
N
A
N /
B
-B
R
BE
CI

87